NASDAQ:INCY - Incyte Stock Price, Forecast & News

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Incyte Co. (NASDAQ:INCY) issued its earnings results on Thursday, February, 13th. The biopharmaceutical company reported $0.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.57 by $0.08. The biopharmaceutical company had revenue of $579.40 million for the quarter, compared to analyst estimates of $558.13 million. Incyte had a net margin of 20.70% and a return on equity of 20.05%. The company's revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.40 EPS. View Incyte's Earnings History.

Incyte is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Incyte.

21 brokers have issued 1 year target prices for Incyte's shares. Their forecasts range from $74.00 to $121.00. On average, they anticipate Incyte's stock price to reach $91.26 in the next year. This suggests a possible upside of 22.7% from the stock's current price. View Analyst Price Targets for Incyte.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 11 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Incyte.

Media coverage about INCY stock has trended very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Incyte earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Incyte.

Incyte saw a decline in short interest during the month of February. As of February 14th, there was short interest totalling 3,980,000 shares, a decline of 12.1% from the January 30th total of 4,530,000 shares. Based on an average trading volume of 1,450,000 shares, the days-to-cover ratio is presently 2.7 days. Approximately 1.9% of the shares of the company are short sold. View Incyte's Current Options Chain.

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and United Therapeutics (UTHR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Array Biopharma (ARRY), Micron Technology (MU) and Celgene (CELG).

Incyte's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Capital International Investors (4.38%), State Street Corp (3.84%), Renaissance Technologies LLC (1.67%), UBS Asset Management Americas Inc. (1.50%), Geode Capital Management LLC (1.36%) and Pictet Asset Management Ltd. (0.88%). Company insiders that own Incyte stock include Barry P Flannelly, Herve Hoppenot, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing. View Institutional Ownership Trends for Incyte.

INCY stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., First Trust Advisors LP, Janus Henderson Group PLC, Panagora Asset Management Inc., Massachusetts Financial Services Co. MA, Raymond James Financial Services Advisors Inc., Amundi Pioneer Asset Management Inc. and Bank of New York Mellon Corp. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing. View Insider Buying and Selling for Incyte.

INCY stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Man Group plc, Los Angeles Capital Management & Equity Research Inc., Capital International Investors, AXA, Jacobs Levy Equity Management Inc., Credit Suisse AG and Teacher Retirement System of Texas. Company insiders that have bought Incyte stock in the last two years include Herve Hoppenot and Jean Jacques Bienaime. View Insider Buying and Selling for Incyte.

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INCY stock can currently be purchased for approximately $74.37.

Incyte has a market capitalization of $16.12 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.View Additional Information About Incyte.

The official website for Incyte is http://www.incyte.com/.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]